NCT00169832View on ClinicalTrials.gov

Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

193

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
DiabetesCoronary Artery Bypass Grafting
Interventions
DRUG

Rosiglitazone or placebo

Rosiglitazone 4 to 8 mg/day or placebo, for 12 months

Trial Locations (9)

B3H 3A7

QEII Health Sciences Center - Halifax Infirmary, Halifax

L8L 2X2

Hamilton Health Sciences - Mc Master Clinic, Hamilton

M5G 2C4

Toronto General Hospital, Toronto

G0C 1E0

CRMSBC, Bonaventure

H2L 4M1

CHUM Notre-Dame Hospital, Montreal

G1V 4G5

Laval Hospital, Sainte-Foy

Unknown

Hospital Del Mar, Barcelona

Hospital Universitari Vall D'Hebron, Barcelona

Hospital Universitarion Son Dureta, Palma de Mallorca

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Laval University

OTHER